AstraZeneca and Global Transparency
Home / Sustainability / Ethics and transparency / AstraZeneca and Global Transparency
Our Approach
AstraZeneca strongly believes that interactions with Health Care Providers (HCPs) and Healthcare Organisations (HCOs) positively influence the quality of patient treatment and the value of medical research.
To provide patients with optimal treatment options, HCPs need to stay informed about the latest developments with current and potential new medicines. The pharmaceutical industry has a duty to provide this information.
HCPs in turn provide the industry with insights into how to improve medicines by feeding back on how they work in real world settings.
We also recognize that patients expect transparency around these relationships to feel confident that HCPs are impartial and always recommend the most appropriate treatment options.
We believe that regulations such as US Open Payments, the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure code, and others across the globe, which require companies to disclose payments and transfers of value made to HCPs and HCOs, will provide greater transparency around these already well-regulated relationships.
Disclosure of Payments and Transfers
The payments and transfers of value disclosed here were made for activities such as providing professional advice about how medicines are used in practice, sharing professional expertise at medical education meetings, taking part in advisory boards, research and educational grants.
AstraZeneca Europe
To download the assumptions and interpretations of the EFPIA Code of Practice for each of our markets, and to download market-level disclosure reports, please click on the country links below.
The 2024 Self Certification Letter affirms AstraZeneca’s commitment to the principles of the EFPIA Code of Practice.
Austria
Belgium
Bulgaria
2023
2022
2021
2020
2019
Croatia
2023
2022
2021
2020
2019
Cyprus
Transparency obligations have been fulfilled per local requirements. Disclosures by KEFEA Members and other EFPIA members operating in Cypress can be found via the following link: http://kefea.org.cy/disclosure-new/
Czech Republic
2023
2022
2021
Denmark
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Estonia
2023
2022
2021
2020
2019
Finland
2023
2022
2021
2020
2019
France
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link: https://www.transparence.sante.gouv.fr/
Transparency obligations have also been fulfilled per EFPIA requirements as it relates to Global transfers of value. Disclosures can be found via the following links:
2023
2023 France EFPIA Disclosure Summary report
2022
2022 France EFPIA Disclosure Summary report
2021
2021 France EFPIA Disclosure Summary report
2020
2020 France EFPIA Disclosure Summary report
2019
2019 France EFPIA Disclosure Summary report
2018
2018 France EFPIA Disclosure Summary report
2017
2017 France EFPIA Disclosure Summary report
Germany
Greece
2023
2022
2021
Hungary
2023
2022
2021
Iceland
There are no payments/transfers of value to disclose.
Ireland
Italy
2023
2022
2021
Latvia
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link:
https://www.vi.gov.lv/lv/pazinojums-par-biedribam-nodibinajumiem-un-arstniecibas-iestadem-sniegto-materialo-vai-cita-veida-atbalstu-2
Transparency obligations have also been fulfilled per EFPIA requirements. Disclosures can be found via the following links:
2023
2022
2021
2020
2019
Lithuania
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link: https://vvkt.lrv.lt/lt/veiklos-sritys/vaistu-reklamos-kontrole/perleistos-vertes/
Transparency obligations have also been fulfilled per EFPIA requirements. Disclosures can be found via the following links:
2023
2022
2021
2020
2019
Luxembourg
Malta
Netherlands
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link: https://www.transparantieregister.nl/home
Norway
2023
2022
2021
2020
2019
2018
2017
Poland
2023
2022
2021
2020
2019
Portugal
Romania
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Russia
2023
2022
2021
2020
2019
Serbia
2023
2022
2021
2020
2019
Slovakia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Slovenia
2023
2022
2021
Spain
Sweden
2023
2022
2021
2020
2019
Switzerland
2023
2022
2021
2020
2019
Turkey
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Ukraine
2023
2022
2021
2020
2019
United Kingdom
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link: www.disclosureuk.org.uk
Alexion Europe
Austria
Finland
2023
2022
Ireland
Italy
2023
2022
Norway
2023
2022
Spain
Sweden
2023
2022
Switzerland
US
For information about US Open Payments, please visit our Physician engagement page or the US Open Payments page managed by the Centers for Medicaid and Medicare Services (CMS).
Alternatively, for information regarding other US specific disclosure activity, please visit the US Corporate Transparency page.
Astrazeneca Asia Pacific
Australia
HCP Payments and Transfers of Value Report
Sponsorship of Third Party Educational Events Report
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Health Consumer Organisations Report
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
New Zealand
HCP and HCO Payments and Transfers of Value Report
Indonesia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Japan
Philippines
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
South Korea
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Alexion Asia Pacific
Australia
HCP Payments and Transfers of Value Report
Sponsorship of Third Party Educational Events Report
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Health Consumer Organisations Report
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Latin America
Brazil State of Minas Gerais
2023
2022
2021
2020
2019
2018
Chile
Colombia
2024
2023
2022
2021
2020
2019
Middle East & Africa
Israel
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Saudi Arabia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Last updated May 2024